B&K (HKSE:02396) Market Cap: HK$452.98 Mil (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02396 B&K Corp Ltd HKSE:02396
8 GF Score
Price HK$3.85
! 1 Warning Sign
View Full Analysis

What is B&K Market Cap?

B&K HKSE:02396 8 Market Cap is HK$452.98 Mil as of Aug. 07, 2026. GuruFocus rates HKSE:02396 with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 1,423 Biotechnology companies, B&K ranks worse than 60.58% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). B&K's share price for the quarter that ended in Dec. 2025 was HK$16.17. B&K's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 117.66 Mil. Therefore, B&K's market cap for the quarter that ended in Dec. 2025 was HK$1,902.53 Mil.

B&K's quarterly market cap stayed the same from May. 2025 (HK$0.00 Mil) to Sep. 2025 (HK$0.00 Mil) but then increased from Sep. 2025 (HK$0.00 Mil) to Dec. 2025 (HK$1,902.53 Mil).

B&K's annual market cap stayed the same from Dec. 2023 (HK$0.00 Mil) to Dec. 2024 (HK$0.00 Mil) but then increased from Dec. 2024 (HK$0.00 Mil) to Dec. 2025 (HK$1,902.53 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. B&K's Enterprise Value for Today is HK$-282.37 Mil.


B&K  (HKSE:02396) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


B&K Market Cap Related Terms


B&K Market Cap Historical Data

* Premium members only.

The historical data trend for B&K's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

B&K Market Cap Chart

B&K Annual Data
Trend Dec23 Dec24 Dec25
Market Cap
0.00 0.00 1,902.53

B&K Quarterly Data
Dec23 Dec24 May25 Sep25 Dec25
Market Cap 0.00 0.00 0.00 0.00 1,902.53

HKSE:02396 vs VRTX, REGN, RVMD: Market Cap Comparison

For the Biotechnology subindustry, B&K's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


B&K Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, B&K's Market Cap distribution charts can be found below:

* The bar in red indicates where B&K's Market Cap falls into.


HKSE:02396
8GF Score
B&K Corp Ltd HKSE:02396
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

B&K Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

B&K's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=HK$16.17*117.658
=HK$1,902.53

B&K's Market Cap for the quarter that ended in Dec. 2025 is calculated as

Market Cap (Q: Dec. 2025 )=Share Price (Q: Dec. 2025 )*Shares Outstanding (EOP) (Q: Dec. 2025 )
=HK$16.17*117.658
=HK$1,902.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of HK$452.98 Mil mean?
B&K (HKSE:02396) has a Market Cap of HK$452.98 Mil as of Aug. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on B&K and its competitors. According to the industry distribution chart, B&K ranks #862 out of 1423 companies in the Biotechnology industry, placing it in the top 60.6%.
Is B&K's Market Cap too high?
B&K's current Market Cap is HK$452.98 Mil. Based on the distribution chart, B&K ranks #862 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, B&K has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does B&K's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, B&K ranks #862 out of 1423 companies for Market Cap. This places B&K in the lower half of its industry. The industry median Market Cap is 116.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.70, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on B&K and its competitors. For the Biotechnology industry, the median Market Cap is 116.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. B&K's current Market Cap is HK$452.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is B&K stock overvalued right now?
B&K (HKSE:02396) has a current Market Cap of HK$452.98 Mil. The current Market Cap is HK$452.98 Mil. B&K's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For B&K (HKSE:02396), the current Market Cap is HK$452.98 Mil as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

B&K Business Description

Address No. 19 Qinling Road, Xiexin Center, Room 1507, Building 1, Laoshan District, Shandong Province, Qingdao, CHN
B&K Corp Ltd is a China-based biopharmaceutical company committed to developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities. The company prominently focuses on the discovery, development and commercialization of therapies for wound healing, currently PDGF drugs. Its pipeline consisted of ten candidates, seven of which are PDGF candidates, including two Core Products, namely Pro-101-1 for the treatment of thermal burns and Pro-101-2 for the treatment of DFUs, which are rhPDGF-BB drugs. The company operates in a single reportable segment: the research and development of biopharmaceutical products. Geographically, the company generates all its revenue from Chinese Mainland.
8GF Score

Get the complete analysis for HKSE:02396

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.85
Price